title: Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
authors: Bristol-Myers Squibb, Princeton, USA james.novotnyjr@bms.com.
authors: J F
authors: JF
authors: Novotny
authors: Bristol-Myers Squibb, Princeton, USA.
authors: J
authors: J
authors: Cogswell
authors: Bristol-Myers Squibb, Princeton, USA.
authors: H
authors: H
authors: Inzunza
authors: Bristol-Myers Squibb, Princeton, USA.
authors: C
authors: C
authors: Harbison
authors: Bristol-Myers Squibb, Princeton, USA.
authors: C
authors: C
authors: Horak
authors: Bristol-Myers Squibb, Princeton, USA.
authors: S
authors: S
authors: Averbuch
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000096:biosynthesis
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab